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Abstract BDV naturally infects horses and sheep, and causes 
sporadic neurological disease. Serological evidence suggests an 
association of BDV, or a related virus, with specific psychiatric 
diseases in humans. Here, by using a nested RT-PCR technique, 
we demonstrate that human BDV RNA is present in the PBMC 
of psychiatric patients. In an examination of a total of 60 patients 
from 5 wards of a hospital in Japan, the detection rate differed 
within each ward, ranging from 8% to > 50% (37% on the aver- 
age). Of particular note was the finding that the human derived 
BDV sequences, which included deleted forms in about 23% of 
the positive samples, were slightly different from those derived 
from horse BDV. These results suggest urgent consideration of 
the measures to be taken to cope with the effects of blood trans- 
fusion. In addition, the detection of a high level of BDV in the 
PBMC of patients will help our understanding of the pathogenesis 
in the disease. 
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1. Introduction 
BDV is a neurotropic, yet unclassified, nonsegmented, nega- 
tive-sense, single-stranded RNA virus which naturally infects 
horses, sheep, cats, cattle, and ostriches [1]. Serological data 
suggest an association of BDV, or a related agent, with specific 
psychiatric diseases in humans [2,3], although healthy people 
also contain a low prevalence of anti-BDV antibodies [4,5]. 
Experimental BDV infection of animals such as rats induces 
behavioural changes that resemble some types of affective neu- 
ropsychiatric disorders in humans [1]. However, whether BDV 
is a natural pathogen of humans remains to be determined as 
infectious BDV, or related virus, has yet to be isolated from 
human tissue or body fluids. 
Borna disease has been most extensively characterized in 
experimentally infected rats, in which the agent is highly neuro- 
virulent invading the brain from peripheral sites by axonal 
transport [6]. By an RT-PCR technique, the BDV-specific p40 
gene was identified in the brain and many peripheral organs of 
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intranasally infected rats although it was not found in blood [7]. 
In contrast, the presence of the gene was also demonstrated by 
a similar technique in PBMC of neonatally, intracranially in- 
fected rats [8]. In naturally BDV-infected horses however, the 
presence of BDV-specific RNA has been demonstrated by a 
similar technique in brain tissue [9], and in conjunctival fluid, 
nasal secretions and saliva [10]. In addition, many seropositive 
samples from horses were negative by RT-PCR [10], indicating 
either that BDV is shed irregularly and in intervals or that the 
BDV genome is sufficiently variable in a number of seropositive 
animals to evade detection by this technique. 
Here, we examined the possible presence of BDV-specific 
RNA in PBMC from humans with psychiatric disorders. For 
this, we developed a more sensitive technique, nested RT-PCR, 
for the amplification of a fragment of p24, a region which is 
relatively well conserved within BDV genomes [11]. 
2. Materials and methods 
2.1. Patients 
We studied PBMC from 35 males aged 34~ 69 from three wards and 
25 females aged 37-73 from two further wards in a local psychiatric 
hospital in Hokkaido (Table 1). PBMC was isolated from EDTA- 
treated blood by centrifugation on Ficoll Paque (density 1.077). 
2.2. BDV and cells 
MDCK cells uninfected or persistently infected with BDV (MDCK/ 
BDV; kindly provided by Dr. R. Rott, Justus-Liebig-Universit~it Gies- 
sen, Giessen, Germany) [12] were used. 
2.3. Preparation of cellular RNA 
Total RNA fractions were prepared by using an RNA extraction kit 
(RNAzol B; Cinna/Biotecx Laboratories International, Inc., Friends- 
wood, TX, USA) as described [13]. 
2.4. Detection of BD V RNA 
For the detection of BDV-specific RNA genome, nested RT-PCR 
was used. One microgram of total cellular RNA was used in a reverse 
transcription reaction, followed by an amplification reaction of cDNA 
using the EZ rTth RNA PCR kit (Perkin-Elmer Corporation, Branch- 
burg, N J, USA) with a primer pair 5'-TGACCCAACCAGTAGAC- 
CA-Y (Bo-p24.D2) at nucleotides 1,387 to 1,405 and 5'-GTCCCAT- 
TCATCCGTTGTC-3' (Bo-p24.A1) at nucleotides 1,865 to 1,847 of the 
BDV genome. The reverse transcription step was performed in a total 
volume of 50 microliters in a thermal cycler (Perkin-Elmer Corpora- 
tion) at 60°C for 30 rain, followed by 93°C for 2 min. The reverse 
transcription products were subsequently subjected to the amplification 
for 35 cycles of denaturation at 94°C for 1 min and annealing and 
polymerization at60°C for 1.5 min, followed by a final polymerization 
step for 10 min at 60°C. Five microliters of the RT-PCR product were 
used in a second PCR with a nested set of primers, 5'-TCAGACCC- 
AGACCAGCGAA-3' (Bo-p24.D3) at nucleotides 1,443 to 1,461 and 
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5'-AGCTGGGGATAAATGCGCG-3' (Bo-p24.A2) at nucleotides 
1,834 to 1,816. The 2nd PCR consisted of 35 cycles of denaturation at 
94°C for 1 min, annealing at 57°C for 1 min, and polymerization at 
72°C for 1.5 min, followed by a final polymerization step for 7 min at 
72°C. The PCR products were separated by 1.5% agarose gel electro- 
phoresis, blotted onto a nylon membrane, then hybridized with 32p_ 
labeled synthetic oligonucleotides, sense stranded nucleotides (1,462 to 
1,484 [Bo-seq.D1], 1,485 to 1,507 [Bo-seq.D2] and 1,637 to 1,658 [Bo- 
seq.D3] and an antisense stranded nucleotide (1,791 to 1,811 [Bo- 
seq.Al]). In addition, the PCR products were cloned in a pCRII vector 
using a TA cloning kit (Invitrogen Corporation, San Diego, CA, USA) 
and several representative clones were sequenced according to the pro- 
tocol described for the CircumVent Thermal Cycle Dideoxy Sequencing 
Kit (New England Biolabs Ltd., Beverly, MA, USA) using 32p-labeled 
primers, Bo-p24.D3 and Bo-p24.A2. The PCR products were also di- 
rectly sequenced by the method of Engelke t al. [14] using 32p-labeled 
primers, Bo-Seq.D1 and Bo-Seq.A1. All the numbers for BDV nucleo- 
tide sequences described here correspond to the previously reported 
BDV numbering scheme [15]. 
2.5. Detection of anti-BD V antibodies 
For detection of anti-BDV antibodies inplasma from the same blood 
samples as those used for the PBMC preparations, full-length p24 
protein prepared as a fusion protein with GST in E. coli [16] was used 
as an antigen for Western blot. GST was used as a negative control 
protein. Both GST-p24 and GST proteins were used after purification 
by glutathione Sepharose 4B (Pharmacia Biotech AB, Uppsala, Swe- 
den) column chromatography. 
3. Results 
A 
3.1. Detection o f  BD V RNA in PBMC 
When the nested RT-PCR technique was applied to the de- 
tection of BDV-related RNA in the PBMC from 60 psychiatric 
inpatients, clear positive signals were detected in 36.7% (22160) 
of the samples by both ethidium bromide staining and Southern 
blotting (Table 1). Most of the PCR products howed a discrete 
band corresponding to the size (374 bp) of the fragment from 
persistent BDV in MDCK cells. However, patient numbers 9, 
27 and 57 showed a band with slightly increased mobility, while 
patient number 26 showed a band with much faster mobility. 
Patient number 42 showed two bands, one with normal and one 
with faster mobility. The results of the staining and Southern 
blots of patient numbers 25 to 36 in Table 1 are shown in Fig. 
1 as representative of the total analysis obtained. Sequence 
results from the random sampling of the PCR products howed 
some differences from the reported sequences (He/80-1, Strain 
V and WT- 1) of horse-derived BDV [ 11,15] (Fig. 2). In addition, 
one (pHBDV-9-27) of two DNA clones derived from the prod- 
ucts with normal size (patient numbers 8 and 9 in Table 1) 
contained a one base deletion which results in the appearance 
of stop codon just after the deletion site. Direct sequencing of 
two forms (HBDV-26 and -27) of RT-PCR products with 
smaller sizes revealed misalignment mutations which generate 
large deletions of 230 bases from nucleotides 1,489 to 1,718 and 
115 bases from nucleotides 1,503 to 1,617, respectively. For this 
deletion mechanism, repeat sequences AATGATG and AAG, 
respectively, seem to play a role, as has been similarly reported 
in retroviruses [17]. Thus, most of the BDV in PBMC from 
certain patients was homogeneous and contained only the same 
mutant form. 
3.2. Detection o f  ant i -BDV antibodies in plasma 
The plasma from the same blood samples used for the BDV 
genome-positive PBMC preparations were also examined for 
the presence of anti-BDV antibodies (Table 1). Western blot 
analysis was done using purified GST-BDV p24 fusion protein 
as the test antigen. The results showed a 30% seroprevalence 
(18/60) when 1:50 dilutions of plasma were used (Table 1). Only 
i 
1 2 3 4 5 6 ~ 7 8 9 10 11 12 (+) ~ (-) 
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Fig. 1. Nested RT-PCR for the detection of BDV RNA in PBMC from psychiatric inpatients. Representative results of 12 samples (the same samples 
shown as patient numbers 25 to 36 in Table 1) analyzed by nested RT-PCR are shown here. The products of PCR amplification of the BDV p24 
region were subjected to agarose gel electrophoresis, then stained with ethidium bromide (A). The results of the Southern blot hybridization using 
four oligomers as a probe are also shown (B). As positive and negative controls, the RNA fractions from MDCK/BDV (+) and MDCK (-) were 
similarly subjected to nested RT-PCR. DW means distilled water in place of the RNA. MW indicates the size markers (q~x DNAIHaeIII fragments). 
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9 o f  the  60  pat ients  (15%)  showed pos i t ive  s igna ls  by  both  
RT-PCR and Western  b lo t  ana lyses  (Tab le  1). 
4. Discussion 
Our  s tudy  has  demonst ra ted  the  presence  o f  BDV genomic  
sequences  in PBMC f rac t ions  f rom psych ia t r i c  inpat ients  by  a 
nested  RT-PCR techn ique  (F ig .  1). A recent  repor t  [18] that  
some para formaldehyde- f ixed  monocytes  in  the  PBMC f rom 
psych ia t r i c  inpat ients  were  pos i t ive  fo r  BDV ant igens  by  f low 
cytometry  wou ld  be  in  agreement  w i th  our  resu l ts .  More  re-  
cent ly ,  the  same group a lso  demonst ra ted  the  presence  o f  BDV-  
Table 1 
Profi les o f  60 pat ients  in 5 wards  and  their  summar ized  results for  BDV 
Ward  Pat ient  Sex Age BDV genome in PBMC Size o f  PCR product  Serum ant ibody  a 
A 1 M 52 + normal  + 
A 2 M 61 + normal  - 
A 3 M 52 - 
A 4 M 65 - 
A 5 M 63 - 
A 6 M 38 + normal  + 
A 7 M 47 - + 
A 8 M 63 + normal  + 
A 9 M 61 + small delet ion + 
A 10 M 43 - 
A 11 M 66 - 
B 12 M 56 - 
B 13 M 49 - 
B 14 M 62 - 
B 15 M 69 - 
B 16 M 42 - + 
B 17 M 42 - + 
B 18 M 41 + normal  + 
B 19 M 51 - 
B 20 M 34 - 
B 21 M 52 - 
B 22 M 53 - 
B 23 M 60 - + 
C 24 M 44 - 
C 25 M 56 - 
C 26 M 58 + large delet ion - 
C 27 M 64 + small delet ion - 
C 28 M 58 + normal  + 
C 29 M 62 - + 
C 30 M 43 - 
C 31 M 62 - 
C 32 M 62 + normal  + 
C 33 M 56 + normal  - 
C 34 M 53 - + 
C 35 M 65 + normal  + 
D 36 F 70 - 
D 37 F 67 - 
D 38 F 37 - + 
D 39 F 60 - + 
D 40 F 73 + normal  - 
D 41 F 54 - 
D 42 F 42 + normal  & small deletion - 
D 43 F 40 - 
D 44 F 52 - 
D 45 F 63 - 
D 46 F 62 + normal  - 
D 47 F 70 - 
E 48 F 53 - 
E 49 F 62 + normal  - 
E 50 F 62 + normal  + 
E 51 F 54 - 
E 52 F 69 - 
E 53 F 63 + normal  - 
E 54 F 64 - 
E 55 F 55 + normal  - 
E 56 F 47 + normal  - 
E 57 F 52 + small delet ion - 
E 58 F 42 + normal  - 
E 59 F 61 - + 
E 60 F 62 - 
"P lasma fract ion (1 :50 di lut ion in PBS) was appl ied to Western b lot t ing using purif ied GST-BDV p24 fusion protein.  
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A 
He/80-1  
S t ra in  V 




S t ra in  V 
WT- I  
p; IBDV-8-22 
pSBDV-9-27  
1671 1681 1691 1701 1711 1721 
I i I I I I 
CTT GGC GAG AAC ATC AAG ATA CTG GAT CGC TCC ATG AAG ACA ATG ATG GAG ACA ATG AAG 
- -C  . . . . . . . . . . . . . . . . . . . .  A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
- -C  - -T  . . . . . . .  C-  - -A  G . . . . . . . . . . .  C . . . . . . . . . . . . . .  T . . . . .  G - -  G . . . . .  
- -C  - -T  . . . . . .  G . . . . . . . .  T . . . . . . . . .  z -  -~  Ik . . . . . . . . .  C . . . . . . . . . . . . .  
1731 1741 1751 1761 1771 1781 
I i I J I I 
CTC ATG ATG GAG AAG GTG GAC CTC CTC TAC GCA TCA ACC GCC GTT GGG ACC 
. . . . . . . . . . . . . . . . . . . .  T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . .  G . . . . . .  C - -T  . . . . . . . . . .  G-  . . . .  A . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . .  TT  . . . . . . . . . . . . . . . .  A . . . . . .  A . . . . . .  
1~ 1464 I~89 17~e 1730 
I J I I 
He/80-1  CCG AAG GGA CAG CTA TCG AAT GAT GAG // - - - A C A  ATG ATG GAG ACA ATG AAG 
HBDV-26 CCG AAG GGA CAG CTG TCG AAT GAT GAe (A 230 basa l )  ~e . IL  A~ A~ GAG ACA ATG AAG 
1482 1503 ~617 1634 
i I I I 
He/80-1  AAT GAT GAG CTT  ATC AAG AAG CTA // - - C A A  GTG GAA ACC ATC CAG ACA 
HBDV-27 AAT GAT GAG CTA ATC AAG AA.__GG CT&- -  (A 115 ~ lem)  ~ OTG GAA ACC ATC CAG ACA 
Fig. 2. Comparison of p24 sequence derived from human PBMC BDV and previously reported horse-derived BDV. The sequence results of p24 at 
nucleotides 1,671 to 1,781 in two cDNA clones (pHBDV-8-22 and pHBDV-9-27) corresponding to patients 8and 9 in Table 1 are shown in section 
A. The sequences (He/80-1, Strain V and WT-1) of horse-derived BDV which were reported previously [11,15] are also shown in section A. ~:', adeleted 
nucleotide, rJ~'.,, a stop codon appeared by one-base deletion at nucleotide 1,702. The PCR products with increased mobility in Fig. 1 (HBDV-26 
and -27 derived from patients 26 and 27, respectively, in Table 1) were sequenced irectly and the results are shown in section B. As a control, 
horse-derived sequence of He/80-1 [15] is shown. A, deletion. Direct repeats observed at deletion junctions in HBDV-26 and -27 are underlined and 
the sequences and region deleted are shown in outline. 
specific RNA in humans by similar technique as us [19]. Essen- 
tially, their result seems to be almost similar with our result. 
However, sequence analysis of the PCR products in this report 
revealed mutant forms of the BDV genome in PBMC from a 
significant proportion of the patients examined, irrespective of 
the presence or absence of anti-BDV antibodies (Table 1). In 
addition, the sequences obtained were slightly different from 
those of horse-derived BDV genome (Fig. 2). Thus, further 
studies are necessary in order to confirm the pathogenicity of 
BDV and to clarify the relationship between the human BDV- 
related agent and horse BDV. 
The hypothesis that there is an association of BDV with 
psychiatric disorders in humans is due to the high prevalence 
ofanti-BDV antibodies in those patients [2-5]. However, before 
the pathogenesis of BDV in human psychiatric disorders can 
be fully understood, screening for the BDV genome in healthy 
donors and horses or sheep is clearly urgent for a thorough 
understanding of the epidemiology of BDV. The PBMC sam- 
ples examined here were derived from inpatients of Hokkaido, 
the northernmost island of Japan. Many imported horses and 
sheep are bred and maintained in Hokkaido and one possibility 
is that BDV has been transmitted from horses to humans. In 
fact, our examination using RT-PCR as used here has demon- 
strated that BDV is endemic in healthy horses in Hokkaido 
(about 30% prevalence in 57) [20]. In addition, BDV RNA was 
also demonstrated in PBMC from healthy peoples (about 6.5% 
prevalence in 77; M. Kishi, unpublished). In conclusion, our 
results strongly support the hypothesis that the BDV-related 
agent or agents we have identified is a hematopoietic cell-re- 
lated virus that presumably develops disease in the brain only 
after a long-term persistent incubation period. To confirm these 
findings, more widespread screening for BDV is urgently re- 
quired. In particular, measures to cope with the possibility of 
virus transmission by blood transfusion would seem to be espe- 
cially important. 
Acknowledgements." We thank Dr. R. Rott (Justus-Liebig-Universit~it 
Giessen, Giessen, Germany) and Dr. I.M. Jones (NERC Institute of 
Virology, Oxford, UK) for careful review of the manuscript. 
References 
[1] de la Torre, J.C. (1994) J. Virol. 68, 7669-7675. 
[2] Rott, R., Herzog, S., Fleischer, B., Winokur, A., Amsterdam, J.
Dyson, W. and Koprowski, H. (1985) Science 228, 755- 
756. 
[3] Bode, L., Riegel, S., Ludwig, H., Amsterdam, W., Lange, W. and 
Koprowski, H. (1988) Lancet ii, 689. 
[4] Richt, J.A., Herzog, S., Pyper, J., Clements, J.E., Narayan, O., 
Bechter, K. and Rott, R. (1993) Arch. Virol. Suppl. 7, 101 109. 
[5] Bode, L., Ferszt, R. and Czech, G. (1993) Arch. Virol. Suppl. 7, 
159 167. 
[6] Carbone, K.M., Duchala, C.S., Griffin, J.W., Kincaid, A.L. and 
Narayan, O. (1987) J. Virol. 61, 3431 3440. 
[7] Shanker, V., Kao, M., Hamir, A.N., Sheng, H., Koprowski, H. 
and Dietzschold, B. (1992) J. Virol. 66, 992 998. 
[8] Sierra-Honigmann, A.M., Rubin, S.A., Estafanous, M.G., 
Yolken, R.H. and Carbone, K.M. (1993) J. Neuroimmunol. 45, 
31-36. 
[9] Zimmermann, W., Durrwald, R. and Ludwig, H. (1994) J. Virol. 
Methods 46, 133-143. 
[10] Richt, J.A., Herzog, S., Haberzettl, K. and Rott, R. (1993) Med. 
Microbiol. Immunol. 182, 293-304. 
[11] Schneider, EA., Briese, T., Zimmermann, W., Ludwig, H. and 
Lipkin, W.I. (1994) J. Virol. 68, 63 68. 
[12] Herzog, S. and Rott, R. (1980) Med. Microbiol. Immunol. 168, 
153 158. 
[13] Chomczynski, E and Sacchi, N. (1987) Anal. Biochem. 162, 15f~ 
159. 
M. Kishi et al./FEBS Letters 364 (1995) 293-297 297 
[14] Engelke, D.R., Hoener, P.A. and Collins, F.S. (1988) Proc. Acad. 
Natl. Sci. USA 85, 544-548. 
[15] Cubit, B., Oldstone, C. and de la Torre, J.C. (1994) J. Virol. 68, 
1382-1396. 
[16] Weiss, S., Konig, B., Morikawa, Y. and Jones, I. (1992) Gene 121, 
203 212. 
[17] Pathak, V.K. and Temin, H.M. (1990) Proc. Natl. Acad. Sci. USA 
87, 6024--6028. 
[18] Bode, L., Steinbach, F. and Ludwig, H. (1994) Lancet 343, 297- 
298. 
[19] Bode, L., Zimmermann, W., Ferszt, R., Steinbach, F. and Ludwig, 
H. (1995) Nature Medicine 1,232 236. 
[20] Nakamura, Y., Kishi, M., Nakaya, T., Asahi, S., Tanaka, H., 
Sentui, H., Ikeda, K. and Ikuta, K. Vaccine, in press. 
